Last reviewed · How we verify
Carcinoma of breast
Approved treatments
- Ixempra Kit · R-Pharm Us Llc
Ixempra Kit works by disrupting cell division, preventing cancer cells from growing and multiplying. - Ellence · Pfizer
Ellence works by intercalating DNA and inhibiting topoisomerase II, disrupting cancer cell growth. - Afinitor · Novartis
Afinitor works by blocking the mTOR protein, which is involved in cell growth and division. - Taxol · Pfizer
Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. - adriacin · Chipscreen Biosciences, Ltd.
- Hydroxydaunorubicin · University of Colorado, Denver
- Afinitor · Central European Society for Anticancer Drug Research
- Cyclophosphamid · Zhejiang University
- Taxotere · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Docetaxol · Fudan University
- Cytoxan (Lyophilized) · Baxter
Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites. - Taxol · Pfizer
- Liposomal Doxorubicin · Pfizer
- Taxotere · Sanofi
Taxotere works by binding to microtubules, preventing them from disassembling and thereby blocking cell division. - Taxol · Pfizer
- Doxorubicin Hydrochloride · Pfizer
Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division. - Cytoxan (Lyophilized) · Baxter
Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells. - Hydroxydaunomycin · Weill Medical College of Cornell University
- Epidoxorubicin · Hoffmann-La Roche
- Abraxane · The First Affiliated Hospital with Nanjing Medical University
- Adriamycin · Johann Wolfgang Goethe University Hospital
- Taxol · M.D. Anderson Cancer Center
Clinical guidelines
- FDA label — 2L|adjuvant
Docetaxel is indicated for locally advanced or metastatic breast cancer after failure of prior chemotherapy. It is also indicated in combination with doxorubicin and cyclophosphamide for adjuvant treatment of operable node-positive breast cancer.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Carcinoma of breast patent landscape — cliff calendar, originator estates, attackable patents
- Carcinoma of breast treatment landscape brief
- Carcinoma of breast treatment updates RSS
Frequently asked questions about Carcinoma of breast
What drugs treat Carcinoma of breast?
Tracked treatments include Ixempra Kit, Ellence, Afinitor, Taxol, adriacin, Hydroxydaunorubicin, Cyclophosphamid, Taxotere.
What is the treatment for Carcinoma of breast?
Standard treatment for Carcinoma of breast includes Ixempra Kit, Ellence, Afinitor, Taxol, adriacin. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Carcinoma of breast?
FDA label publishes guidelines for Carcinoma of breast. 1 guideline references tracked.
Related
- Treatment landscape: Carcinoma of breast patent cliff · Carcinoma of breast CI report
- Treatment: Ixempra Kit · R-Pharm Us Llc
- Treatment: Ellence · Pfizer
- Treatment: Afinitor · Novartis
- Treatment: Taxol · Pfizer
- Treatment: adriacin · Chipscreen Biosciences, Ltd.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing